Written by people
in the field.
Practical guidance on USP compliance, inspection preparation, and quality management — written by a practicing 503A compounding pharmacist, not a marketing team.
USP 797 Revised: What Changed and What It Means for Your 503A Pharmacy
The 2023 revision to USP 797 introduced significant changes to beyond-use dating, environmental monitoring, and sterility testing requirements. Here is what 503A sterile compounders need to understand — and what it means for your existing SOPs and workflows.
Read articleHow to Prepare Your Compounding Pharmacy for a State Board Inspection
State Board inspectors are not looking for perfection — they are looking for documentation that proves consistent, controlled practice. This is the inspection preparation framework we use with 503A pharmacies, based on what inspectors actually ask for.
Read articleUSP 795, 797, and 800: A Practical Overview for 503A Pharmacies
Most compliance resources explain what each USP chapter says. This one explains how they interact — and where 503A pharmacies most commonly fall short when trying to comply with all three simultaneously.
Read articleWhy Generic QMS Software Fails Compounding Pharmacies
General-purpose quality management systems were built for manufacturing, not pharmacy. The gap between what those platforms offer and what a 503A pharmacy actually needs is significant — and the adaptations required to close it introduce more risk than they eliminate.
Read articleEnvironmental Monitoring for 503A Sterile Compounders — What USP 797 Actually Requires
Environmental monitoring is one of the most documentation-intensive requirements in USP 797 — and one of the most common areas where pharmacies fall short during inspections. Here is what a defensible EM program looks like in practice.
Read articleSee the platform behind the guidance.
CRAVE automates the workflows these articles describe — so your team spends less time managing compliance and more time compounding.